Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension

AYPAR E., ALEHAN D., KARAGÖZ T., AYKAN H. H., ERTUĞRUL İ.

CARDIOLOGY IN THE YOUNG, cilt.28, sa.4, ss.542-547, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 4
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1017/s1047951117002542
  • Dergi Adı: CARDIOLOGY IN THE YOUNG
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.542-547
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background Macitentan is an orally active, potent, dual endothelin receptor antagonist and is the only registered treatment for pulmonary arterial hypertension that significantly reduced morbidity and mortality in a long-term event-driven study.